Skip to content

The Effect of Haemothorax Auto-Transfusion on Coagulation and Haemostasis (HATCH): A Prospective Self-Controlled Interventional Study

The Effect of Haemothorax Auto-Transfusion on Coagulation and Haemostasis (HATCH): A Prospective Self-Controlled Interventional Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202607785550678
Enrollment
10
Registered
2026-07-29
Start date
2026-08-03
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Injury, Occupational Diseases, Poisoning

Interventions

Haemothorax autotransfusion

Sponsors

Haemonetics Corporation are providing in kind device support by lending us the TEG6S analyser and providing cartridges for use
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: • Adults aged =18 years. • Haemothorax requiring drainage via ICC in the TEU. • A requirement for transfusion of blood products in the opinion of the treating clinician. Transfusion decisions in the TEU are made by senior medical staff based on clinical assessment of haemodynamic status, indicators of end-organ perfusion, and degree of ongoing blood loss; there is no formal protocolised trigger.

Exclusion criteria

Exclusion criteria: • Known pre-existing coagulopathy. • Known use of anticoagulant or antiplatelet medication within 7 days. • Suspicion of pleural blood contamination – defined as penetrating thoracoabdominal injury with suspected diaphragmatic injury and clinical or radiographic signs of concomitant hollow viscus injury (e.g. peritonism, haematemesis, or subdiaphragmatic free air). • Known malignant mesothelioma. • Enrolment in another interventional study likely to influence coagulation outcomes.

Design outcomes

Primary

MeasureTime frame
Within-subject changes in R time, as measured by TEG viscoelastic assay

Secondary

MeasureTime frame
• Within-subject changes in other TEG parameters (K time, a angle, maximum amplitude [MA], LY30) between T0 and T1. • Within-subject changes in PlateletMapping parameters (MA-ADP, MA-AA, MA-fibrin, percentage inhibition ADP, percentage inhibition AA) between T0 and T1. • Within-subject changes in venous blood gas parameters (haemoglobin, pH, ionised calcium, and lactate) between T0 and T1. ;In-hospital mortality, the documented incidence of sepsis, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute kidney injury (AKI).

Countries

South Africa

Contacts

Public ContactNicholas Chapman

Trauma Registrar at Chris Hani Baragwanath Academic Hospital

nicholaschapman.nz@gmail.com+61416593323

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026